Find Inactive Ingredients Include, Trehalose Human Albumin Sodium Glutamate, Vaccine Biotechnology Long Validity Period on Industry Directory, Reliable Manufacturer/Supplier/Factory from China.

Home > Products > Syringe > Pre-filled Syringe Varicella Vaccine Lyophilized

Pre-filled Syringe Varicella Vaccine Lyophilized

Pre-filled Syringe Varicella Vaccine Lyophilized

Basic Info

Model No.: 0.5ml/vial

Product Description

[Immune procedures and dosage]

(1) One dose of basic immunization for children of 1-12 years old; two doses of basic immunization for people of 13 years old and above with 4-8 weeks of interval.

(2) Transfer the diluent with a Syringe into the vial containing lyophilized vaccine. Shake well to ensure complete dissolution of the pellet for use and transfer all the liquid back to the syringe.

(3) Apply 0.5 ml suspension for subcutaneous injection at the deltoid area of the upper arm.

According to the epidemic data and clinical research literatures at home and abroad, the Health Authorities in the provincial level or above can make one-dose booster immunization for people below 12 years old based on the local epidemic surveillance if necessary.


Changchun BCHT Biotechnology Co.,Ltd


BCHT was established in March 2004 by the investment of Changchun High-technology Industry Development Property (Group). The company is a high-tech enterprise engaged in research, development, production and marketing of biologics and drugs. BCHT now owns four manufacturing sites which cover 235,000 square meters in total and two R&D centers for vaccine and drug with the most equipped laboratories and pilot plants in the areas over 5000 square meters. For the last few years, the company`s R&D investment exceeds over 120 million RMB.

In 2008, BCHT successfully launched its product Varicella Vaccine, Live in China. In the following years, BCHT continuously committed to improving the product and led in 2010 removal of gelatin from adjuvant and extended the vaccine shelf-life up to 36 months which is the longest one in the world in 2011. These improvements enhanced the vaccine safety and quality, and established BCHT the leading position in varicella vaccine.

Jilin Maifeng Biopharmaceutical Co., Ltd., a subsidiary of BCHT, is devoted to mostly R&D in high density cell culture technique and its application for large scale production. Jilin Maifeng is the first company to develop and apply the self-developed microcarrier bioreactor technology to produce rabies vaccine for human use.

Company Info

  • Company Name: Changchun BCHT Biotechnology Co.,Ltd
  • Product/Service: Varicella Vaccine , Rabies Vaccine for Human Use , Bulk of Varicella Vaccine , Bulk of Rabies Vaccine , PFS Varicella Vaccine , Exenatide Acetate
  • Capital (Million US $): US$0.2Million
  • Year Established: 2004
  • Total Annual Sales Volume (Million US $): US$1 Million - US$2.5 Million
  • Export Percentage: 1% - 10%
  • Total Annual Purchase Volume (Million US $): Below US$1 Million
  • No. of Production Lines: 4
  • No. of R&D Staff: 51 -60 People
  • No. of QC Staff: 91 -100 People
  • OEM Services Provided: no
  • Factory Size (Sq.meters): Above 100,000 square meters
  • Factory Location: 1260Huoju Road,Changchun High-tech Zone,Changchun,Jilin,China
  • Contact Person: Mr. Jason Jiang
  • Tel: 86-0431-87078891
Email to this supplier
  • *Subject:
  • To:

  • *Messages:
    Your message must be between 20-8000 characters